Coronavirus Both are used against arthritis
The British National Health Service are set to start using a rheumatoid arthritis medicine to treat severe cases of the coronavirus. The medicine has been found to reduce the risk of death by 24 percent.
Results of a new scientific study into two anti-inflammatory drugs – tocilizumab and sarilumab – showed that they saved the lives of one in 12 patients in intensive care.
A previous study had suggested that tocilizumab was useful to fight against severe cases, but two further studies proved inconclusive.
This latest research was carried out on more than 3,900 COVID-19 patients in 15 countries around the world.
According to The Guardian, researchers randomly assigned patients to receive standard treatment, and others to receive injections of tocilizumab or sarilumab.
The result of 792 patients in six countries showed a reduce risk of death. There was a 35.8 percent chance of mortality of those who received standard care, and 28 percent for those who received tocilizumab, and 22.2 percent for this who were treated with sarilumab.
The cost of the medicines is between 800 and 1,100 euros per patient.